Congruence Therapeutics Email Format

Biotechnology ResearchQuebec, Canada11-50 Employees

Congruence Therapeutics is a small-to-mid-sized biotechnology company that uses computational methods to develop small molecule correctors aimed at restoring normal protein function in diseases driven by protein misfolding. Its Revenir platform analyzes proteins across their conformational ensembles to reveal binding pockets, including allosteric and cryptic sites, which are then virtually screened to generate novel chemical matter. The company is pursuing a pipeline of pharmacological correctors for conditions such as MC4R-deficient obesity, GBA1-driven Parkinson's disease, and Alpha-1 antitrypsin deficiency. These efforts focus on diseases where misfolded proteins contribute to pathology. Based in Saint-Laurent, Quebec, Congruence operates in the biotechnology research sector and collaborates with external partners on oncology drug discovery under option-type agreements established in December 2024. In April 2026, the company announced its participation in the 25th Annual Needham Virtual Healthcare Conference, signaling ongoing activity in both clinical development and corporate engagement.

Get verified Congruence Therapeutics emails free

Company overview Employee directory